Efficacy of Pharmacological Therapies for the Treatment of Opioid-Induced Constipation: Systematic Review and Meta-Analysis
Authors:
- Alexander C FordAFAlexander C Ford
- Darren M BrennerDBDarren M Brenner
- Philip S SchoenfeldPSPhilip S Schoenfeld
- 1 October 2013
- journal article
- review article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 108 (10) , 1566-1574
Abstract
There has been no definitive synthesis of the evidence for any benefit of available pharmacological therapies in opioid-induced constipation (OIC). We conducted a systematic review and meta-analysis to address this deficit. We searched MEDLINE, EMBASE, EMBASE Classic, and the Cochrane central register of controlled trials through to December 2012 to identify placebo-controlled trials of μ-opioid receptor antagonists, prucalopride, lubiprostone, and linaclotide in the treatment of adults with OIC. No minimum duration of therapy was required. Trials had to report a dichotomous assessment of overall response to therapy, and data were pooled using a random effects model. Effect of pharmacological therapies was reported as relative risk (RR) of failure to respond to therapy, with 95% confidence intervals (CIs). Fourteen eligible randomized controlled trials (RCTs) of μ-opioid receptor antagonists, containing 4,101 patients, were identified. These were superior to placebo for the treatment of OIC (RR of failure to respond to therapy=0.69; 95% CI 0.63-0.75). Methylnaltrexone (six RCTs, 1,610 patients, RR=0.66; 95% CI 0.54-0.84), naloxone (four trials, 798 patients, RR=0.64; 95% CI 0.56-0.72), and alvimopan (four RCTs, 1,693 patients, RR=0.71; 95% CI 0.65-0.78) were all superior to placebo. Total numbers of adverse events, diarrhea, and abdominal pain were significantly commoner when data from all RCTs were pooled. Reversal of analgesia did not occur more frequently with active therapy. Only one trial of prucalopride was identified, with a nonsignificant trend toward higher responder rates with active therapy. Two RCTs of lubiprostone were found, with significantly higher responder rates with lubiprostone in both, but reporting of data precluded meta-analysis. μ-Opioid receptor antagonists are safe and effective for the treatment of OIC. More data are required before the role of prucalopride or lubiprostone in the treatment of OIC are clear.Keywords
This publication has 32 references indexed in Scilit:
- Subcutaneous methylnaltrexone for treatment of acute opioid‐induced constipation: Phase 2 study in rehabilitation after orthopedic surgeryJournal of Hospital Medicine, 2011
- Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysisGut, 2011
- Efficacy and Safety of Prucalopride in Patients with Chronic Noncancer Pain Suffering from Opioid-Induced ConstipationDigestive Diseases and Sciences, 2010
- Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trialExpert Opinion on Pharmacotherapy, 2009
- The Prevalence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1)Pain Medicine, 2009
- Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer painCurrent Medical Research and Opinion, 2008
- Gastrointestinal side effects in chronic opioid users: results from a population‐based surveyAlimentary Pharmacology & Therapeutics, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003
- Risk Factors for Chronic Constipation Based on A General Practice SampleAmerican Journal of Gastroenterology, 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986